



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS ANNOUNCES LATE BREAKING ABSTRACT ON EBLASAKIMAB IN COPD ACCEPTED FOR PRESENTATION AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE

**San Mateo, California, and Singapore, April 24, 2024** – ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on *eblasakimab* in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024. The conference is taking place in San Diego, California, from May 17 to 22, 2024.

#### American Thoracic Society International Conference poster details

**Poster title:** *Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Airway Constriction in COPD-Derived Lung Slices (Poster ID 13753)*

**Presentation date and time:** Monday, May 20, 2024, 9:15 am PDT

**Presenter:** Dr Ferda Cevikbas, Head, Translational Science, ASLAN Pharmaceuticals

The posters will be available to view online in the Publications section of ASLAN's [website](#) following presentation.

#### About *eblasakimab*

*Eblasakimab* is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. *Eblasakimab's* unique mechanism of action enables specific blockade of the Type 2 receptor and has the potential to improve upon current biologics used to treat allergic disease. By blocking the Type 2 receptor, *eblasakimab* prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) – the key drivers of inflammation in AD and Type 2-driven COPD. ASLAN announced positive results from the Phase 2b TREK-AD study of *eblasakimab* in moderate-to-severe biologic-naïve AD patients in July 2023, and is currently investigating *eblasakimab* in *dupilumab*-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.

#### About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing *eblasakimab*, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating *eblasakimab* in *dupilumab*-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing *farudodstat*, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the [ASLAN website](#) or follow ASLAN on [LinkedIn](#).



**Ends**

**Media and IR contacts**

**Emma Thompson**

Spurwing Communications

Tel: +65 6206 7350

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

**Ashley R. Robinson**

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: [arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)